行情

STML

STML

Stemline
NASDAQ

实时行情|Nasdaq Last Sale

9.91
+0.43
+4.54%
盘后: 9.91 0 0.00% 16:00 11/15 EST
开盘
9.58
昨收
9.48
最高
10.12
最低
9.44
成交量
69.87万
成交额
--
52周最高
18.22
52周最低
7.82
市值
4.96亿
市盈率(TTM)
-4.1032
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

STML 新闻

  • 关厂风波肆起、显示屏遭质疑:三星能否靠5G绝地求生
  • 蓝鲸TMT.13分钟前
  • 约翰逊承诺结束令经济“陷入瘫痪”的英退不确定性
  • 新浪财经综合.23分钟前
  • 一周财经日历丨美团、拼多多财报出炉,阿里或于周三定价
  • 华盛通.28分钟前
  • 蔚来宣布奉玮出任CFO 后者曾任中金研究部董事总经理
  • 新浪科技.1小时前

更多

所属板块

生物技术和医学研究
+1.25%
制药与医学研究
+1.34%

热门股票

名称
价格
涨跌幅

STML 简况

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.
展开

Webull提供Stemline Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。